
0:00
42:13
Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients.
Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.
More episodes from "Power to the Patients"



Don't miss an episode of “Power to the Patients” and subscribe to it in the GetPodcast app.








